They laughed when he picked Nvidia in 2016…

Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right now

Samina Khan Biography and Net Worth

SVP of Reata Pharmaceuticals

Samina Khan, M.D. joined Reata as Chief Medical Officer in July 2020.

Prior to joining Reata, she served as Clinical Development Team Lead at Mitsubishi Tanabe Pharma America, Inc. from May 2017 to July 2020. From March 2015 to April 2017, Dr. Khan served as Vice President, Clinical Development at Quark Pharmaceuticals, Inc. In her roles at Mitsubishi Tanabe and Quark, Dr. Khan was responsible for clinical science and clinical development. She led large cross functional teams for multiple molecules in her previous positions at Mitsubishi Tanabe and Quark. Prior to March 2015, Dr. Khan served in leadership positions at Abbott Laboratories and AbbVie Inc. Dr. Khan attended Fatima Jinnah Medical University. She completed her residency and fellowship at Tufts Medical Center program and served as an Assistant Professor of Medicine at Tufts University School of Medicine. She also received post-graduate training in rheumatology and immunology. Dr. Khan received an M.P.H. from Harvard Medical School of Public Health and an M.B.A. from Brandeis University.

What is Samina Khan's net worth?: The estimated net worth of Samina Khan is at least $8.08 million as of March 2nd, 2023. Dr. Khan owns 46,905 shares of Reata Pharmaceuticals stock worth more than $8,084,546 as of October 2nd. This net worth evaluation does not reflect any other investments that Dr. Khan may own. Learn More about Samina Khan's net worth.
How old is Samina Khan?: Dr. Khan is currently 58 years old. There are 6 older executives and no younger executives at Reata Pharmaceuticals. The oldest executive at Reata Pharmaceuticals is Mr. Michael D. Wortley, Exec. VP and Chief Legal & Compliance Officer, who is 75 years old. Learn More on Samina Khan's age.
How do I contact Samina Khan?: The corporate mailing address for Dr. Khan and other Reata Pharmaceuticals executives is 5320 LEGACY DRIVE, PLANO TX, 75024. Reata Pharmaceuticals can also be reached via phone at (972) 865-2219 and via email at [email protected]. Learn More on Samina Khan's contact information.
Has Samina Khan been buying or selling shares of Reata Pharmaceuticals?: Samina Khan has not been actively trading shares of Reata Pharmaceuticals over the course of the past ninety days. Most recently, Samina Khan sold 25,000 shares of the business's stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $84.88, for a transaction totalling $2,122,000.00. Following the completion of the sale, the senior vice president now directly owns 46,905 shares of the company's stock, valued at $3,981,296.40. Learn More on Samina Khan's trading history.
Who are Reata Pharmaceuticals' active insiders?: Reata Pharmaceuticals' insider roster includes Bhaskar Anand (CAO), Dawn Bir (Chief Commercial Officer), Elaine Castellanos (CAO), Samina Khan (SVP), Andrea Loewen (SVP), Colin Meyer (Insider), Shamim Ruff (Director), Manmeet Soni (CFO), and Michael Wortley (Insider). Learn More on Reata Pharmaceuticals' active insiders.

Samina Khan Insider Trading History at Reata Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/2/2023	Sell	25,000	$84.88	$2,122,000.00	46,905

Samina Khan Buying and Selling Activity at Reata Pharmaceuticals

Reata Pharmaceuticals Company Overview

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Today's Range

Now: $172.36

$172.32

$172.46

50 Day Range

MA: $171.30

$168.70

$172.36

2 Week Range

Now: $172.36

$21.83

$172.46

Volume

1,988,500 shs

Average Volume

1,091,032 shs

Market Capitalization

$6.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

They laughed when he picked Nvidia in 2016…

From Brownstone Research | Ad

Click here to see why